Background-lIflammatory cytokines, including tumour necrosis factor-a (TNF-a)
Inflammatory cytokines -tumour necrosis factor-a (TNF-a), interleukin-l1 (IL-1,B) and interleukin-6 (IL-6) - Neutralisation of TNF-a by anti-TNF-ao antibodies has recently been suggested to be of therapeutic benefit in Crohn's disease by both open" 12 and controlled therapeutic trials.'3 Therefore cytokine inhibition seems a rational target in treatment of inflammatory bowel disease.
Numerous points of therapeutic intervention to inhibit the synthesis or the action of cytokines are possible.'4 Among them, modulation of cytokine transcription by oxpentifylline (pentoxifylline; PTX), a phosphodiesterase (PDE) inhibitor, has been explored.'5 16 Inhibitors of PDE generate high intracellular cAMP concentrations, which are known to inhibit expression of TNF-ct.'5 16 PTX, the 1-5-oxohexyl analogue of the methylxanthine theobromine, was initially characterised as a haemorrheological agent and has been used in vascular disorders for the past 20 years. PTX has well known pharmacokinetics with minimal side effects.
The present work was designed to evaluate whether PTX reduces the spontaneous and stimulated production of TNF-a, IL-i1 , IL-6, and IL-8 by PBMCs and organ cultures of colon biopsy specimens in patients with inflammatory bowel disease. , and placed in 24 well tissue culture plates in 1 ml culture medium with increasing concentrations of PTX (1 to 100 ,ug/ml). After 24 hours of culture at 37°C in a humidified 95% air/5% CO2 atmosphere, supernatants were removed, filtered, and stored at -80°C until cytokine analysis. Structural integrity of biopsy specimens was assessed by standard histology. Biopsy specimens from each patient were fixed in 1 0% buffered formalin and embedded in paraffin wax after dehydration, clearing, and impregnation. Serial 4 ,um sections were stained with haematoxylin and eosin. Lactate dehydrogenase release in supernatants of cultured tissues was also determined.
Methods

IMMUNOASSAYS FOR CYTOKINES
Culture supernatants were assayed with twosite enzyme linked immunosorbent assays (ELISAs) specific for human interleukins IL-1 ,, IL-6, IL-8, and TNF-cx. Antibodies used were a gift from J Kenney, Antibody Solutions, Half Moon Bay, CA, USA. Quantitative evaluation of monocyte secreted interleukins was achieved by ELISAs using conditions described by Kenney et al,22 with slight modifications as described here. Tween (500 ,u/l PBS) was substituted for thimerosal for the preparation of incubation, blocking, and washing buffers. Polyvinyl chloride pla'tes (Costar, No 2596) were coated with 50 plI per well of antibodies (15 pug/ml) and incubated overnight at 4°C. After the usual wash and non-specific saturation steps, 25 pA standard or sample were added to 25 [lA biotinylated monoclonal antibody (2 pug/ml) and incubated for two hours at room temperature. After washing steps, 50 pA of a peroxidase-streptavidin dilution (1:3000 in PBS Triton) were added and the mixture incubated for one hour at room temperature. A colorimetric reaction (optical density at 450 nm) using o-phenylenediamine dihydrochloride as peroxidase substrate was performed after four washing steps. Concentrations (pg/ml) of unknown samples were computed by interpolation with a standard curve run on each plate using four parameters logistics analysis. . Stimulated IL-6 production and both spontaneous and stimulated IL-8 production by PBMCs were higher in patients with Crohn's disease or ulcerative colitis than in controls. This difference, however, was not significant. Neither disease activity, nor steroid or mesalazine treatment influenced the spontaneous or stimulated cytokine production by PBMCs. When PTX was used, TNF-a concentrations in the supernatants of PBMCs from patients with inflammatory bowel disease were found to be significantly reduced after 24 hours of culture compared with basal production (IC50-25 mg/ml; p<00001) (Fig IA) . The effect of PTX on TNF-ot production by PBMCs from patients with inflammatory bowel disease was the same in the absence or presence of activation by LPS/ PHA (Fig 1B) except for TNF-o at 100 pLg/ml (43% of the basal production without LPS/ PHA v 26% with LPS/PHA; p<0 05). The pattern of the inhibition of PBMC TNF-oa production by PTX in the presence or absence of simultaneous incubation with LPS/PHA did not differ between controls, patients with Crohn's disease, or patients with ulcerative colitis (Fig 2A and 2B) .
PTX did not change the production of IL-1( by PBMCs from patients with inflammatory bowel disease either in the absence or presence of LPS/PHA (p=0-86 without activation by LPS/PHA and p=O-17 with LPS/PHA; Fig 1A  and 1B) . No difference was found between PBMCs from controls, patients with Crohn's disease or patients with ulcerative colitis (for example, p=0-63 for PTX= 100 ,ug/ml with LPS/PHA).
Despite a trend toward higher IL-6 secretion in the presence of PTX, this difference was not significant (p=0-29; Fig 1A) . These results were not modified after LPS/PHA activation (p=0 10; Fig 1 B) . Concentrations of IL-6 in the supernatants of PBMC cultures did not differ between controls, patients with Crohn's disease, and patients with ulcerative colitis.
Concentrations of IL-8 in the cell culture supernatant, in the presence or absence of activation by LPS/PHA (Fig 1A and 1 B) , were not modified by PTX in controls, patients with Crohn's disease, or patients with ulcerative colitis.
The effect of PTX upon cytokine production (particularly TNF-ot production) did not differ according to disease activity, or steroid or mesalazine treatment (data not shown). Non-IBD p<0-28 for TNF-a), or mesalazine treatment CD (for example, p<0-16 for TNF-at).
UC
As found in PBMC cultures, PTX inhibited TNF-o release significantly in organ cultures of intestinal mucosa from patients with inflammatory bowel disease (IC50-25 ,ug/ml; p<O-OOO1) (Fig 3) . Concentrations of PTX exceeding 25 p,g/ml were not able to enhance this inhibitory effect. No difference was seen between patients with Crohn's disease and those with ulcerative colitis (p=0-33). The 00 concentration of TNF-u. inhibition by PTX was not influenced by disease activity (p=0-10), steroid (p=0-57), or mesalazine (p=0-59) treatment.
Concentrations of IL-l,B were significantly decreased in the presence of PTX (about 40% of IL-l,B released spontaneously; p<O-OOO1; Fig 3) by contrast with the effect in PBMC cultures. The effect of PTX was similar in patients with Crohn's disease and those with ulcerative colitis (p=0-93).
Concentrations of IL-6 in the organ culture supematants of inflamed mucosa from patients with inflammatory bowel disease increased significantly in the presence of PTX (144% com-100 pared with spontaneous release; p<00025). inflammatory events associated with inflammatory bowel disease, immunity modifying drugs have been developed, with some of them currently showing promising effects in animal models of experimental colitis or in humans with inflammatory bowel disease. This was, for example, shown by using IL-lra in a rabbit model of formalin immune complex colitis,25 and by using chimeric antitumour necrosis factor monoclonal antibodies in active steroid refractory patients with Crohn's disease.1-13 Such treatments, although effective, are costly and not always well tolerated in humans. Furthermore, their efficacy and their safety in long term use remains to be established.'3 The results, however, strongly suggest that inflammatory cytokines, in particular TNF-a and IL-1, are of major importance in the pathogenesis of inflammatory bowel disease, leading to the evaluation of other cytokine modulating molecules. Whether these drugs act exclusively through cytokine inhibition or involve multiple immune and inflammatory mechanisms remains to be determined. However, as cytokines appear as regulators at the initial steps of intestinal immune response, their inhibition may be a cornerstone in inflammatory bowel disease treatment.
Our results suggest that PDE inhibitors such as PTX may potentially be interesting in the field of cytokine inhibition in patients with Crohn's disease or ulcerative colitis. The difference between response in PBMCs, which was dose related, and the absence of a doseresponse effect in organ cultures remains to be explained. It may be related to the fact that organ cultures represent a complex system in which multiple cells interact. This difference may disappear using lamina propria mononuclear cells instead of organ cultures. Studies are currently in progress in our department to clarify this. Inhibition of IL-i,B in organ cultures but not in PBMCs may also be the result of multiple cell-cell interactions in biopsy specimens. In fact, inhibition of IL-1,B production by PBMCs -as well as down regulation of IL-6 and IL-8 release -by PTX has been reported in vivo under specific culture conditions,26 and described for IL-1 by Bienvenu et a127 using the whole blood model. In conclusion, our data show that PTX down regulates in vitro TNF-a and IL-13 production by PBMCs and intestinal organ cultures from patients with inflammatory bowel disease and indicate a potential interest in this drug and related compounds for treatment of Crohn's disease and ulcerative colitis. 
